Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates

Andrea Marzi, Flora Engelmann, Friederike Feldmann, Kristen Haberthur, W. Lesley Shupert, Douglas Brining, Dana P. Scott, Thomas Geisbert, Yoshihiro Kawaoka, Michael G. Katze, Heinz Feldmann, Ilhem Messaoudi

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Ebola viruses cause hemorrhagic disease in humans and nonhuman primates with high fatality rates. These viruses pose a significant health concern worldwide due to the lack of approved therapeutics and vaccines as well as their potential misuse as bioterrorism agents. Although not licensed for human use, recombinant vesicular stomatitis virus (rVSV) expressing the filovirus glycoprotein (GP) has been shown to protect macaques from Ebola virus and Marburg virus infections, both prophylactically and postexposure in a homologous challenge setting. However, the immune mechanisms of protection conferred by this vaccine platform remain poorly understood. In this study, we set out to investigate the role of humoral versus cellular immunity in rVSV vaccine-mediated protection against lethal Zaire ebolavirus (ZEBOV) challenge. Groups of cynomolgus macaques weredepleted of CD4+T, CD8+T, or CD20+Bcells beforeand during vaccination with rVSV/ZEBOV-GP. Unfortunately, CD20-depletedanimals generated a robust IgG response. Therefore, an additional group of vaccinated animals were depleted of CD4+ T cells during challenge. All animals were subsequently challenged with a lethal dose of ZEBOV. Animals depleted of CD8+ T cells survived, suggesting a minimal role for CD8+ T cells in vaccine-mediated protection. Depletion of CD4+ T cells during vaccination caused a complete loss of glycoprotein-specific antibodies and abrogated vaccine protection. In contrast, depletion of CD4+ T cells during challenge resulted in survival of the animals, indicating a minimal role for CD4+ T-cell immunityin rVSV-mediated protection. Our results suggest that antibodies playa critical role in rVSV-mediated protection against ZEBOV.

Original languageEnglish (US)
Pages (from-to)1893-1898
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume110
Issue number5
DOIs
StatePublished - Jan 29 2013

Fingerprint

Ebolavirus
Democratic Republic of the Congo
Vesicular Stomatitis
Primates
Glycoproteins
Viruses
T-Lymphocytes
Vaccines
Antibodies
Macaca
Vaccination
Marburgvirus
Biological Warfare Agents
Virus Diseases
Cellular Immunity
Immunoglobulin G

ASJC Scopus subject areas

  • General

Cite this

Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. / Marzi, Andrea; Engelmann, Flora; Feldmann, Friederike; Haberthur, Kristen; Shupert, W. Lesley; Brining, Douglas; Scott, Dana P.; Geisbert, Thomas; Kawaoka, Yoshihiro; Katze, Michael G.; Feldmann, Heinz; Messaoudi, Ilhem.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 5, 29.01.2013, p. 1893-1898.

Research output: Contribution to journalArticle

Marzi, A, Engelmann, F, Feldmann, F, Haberthur, K, Shupert, WL, Brining, D, Scott, DP, Geisbert, T, Kawaoka, Y, Katze, MG, Feldmann, H & Messaoudi, I 2013, 'Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates', Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 5, pp. 1893-1898. https://doi.org/10.1073/pnas.1209591110
Marzi, Andrea ; Engelmann, Flora ; Feldmann, Friederike ; Haberthur, Kristen ; Shupert, W. Lesley ; Brining, Douglas ; Scott, Dana P. ; Geisbert, Thomas ; Kawaoka, Yoshihiro ; Katze, Michael G. ; Feldmann, Heinz ; Messaoudi, Ilhem. / Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. In: Proceedings of the National Academy of Sciences of the United States of America. 2013 ; Vol. 110, No. 5. pp. 1893-1898.
@article{f6dd432b18d540dba5860049f4643d8e,
title = "Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates",
abstract = "Ebola viruses cause hemorrhagic disease in humans and nonhuman primates with high fatality rates. These viruses pose a significant health concern worldwide due to the lack of approved therapeutics and vaccines as well as their potential misuse as bioterrorism agents. Although not licensed for human use, recombinant vesicular stomatitis virus (rVSV) expressing the filovirus glycoprotein (GP) has been shown to protect macaques from Ebola virus and Marburg virus infections, both prophylactically and postexposure in a homologous challenge setting. However, the immune mechanisms of protection conferred by this vaccine platform remain poorly understood. In this study, we set out to investigate the role of humoral versus cellular immunity in rVSV vaccine-mediated protection against lethal Zaire ebolavirus (ZEBOV) challenge. Groups of cynomolgus macaques weredepleted of CD4+T, CD8+T, or CD20+Bcells beforeand during vaccination with rVSV/ZEBOV-GP. Unfortunately, CD20-depletedanimals generated a robust IgG response. Therefore, an additional group of vaccinated animals were depleted of CD4+ T cells during challenge. All animals were subsequently challenged with a lethal dose of ZEBOV. Animals depleted of CD8+ T cells survived, suggesting a minimal role for CD8+ T cells in vaccine-mediated protection. Depletion of CD4+ T cells during vaccination caused a complete loss of glycoprotein-specific antibodies and abrogated vaccine protection. In contrast, depletion of CD4+ T cells during challenge resulted in survival of the animals, indicating a minimal role for CD4+ T-cell immunityin rVSV-mediated protection. Our results suggest that antibodies playa critical role in rVSV-mediated protection against ZEBOV.",
author = "Andrea Marzi and Flora Engelmann and Friederike Feldmann and Kristen Haberthur and Shupert, {W. Lesley} and Douglas Brining and Scott, {Dana P.} and Thomas Geisbert and Yoshihiro Kawaoka and Katze, {Michael G.} and Heinz Feldmann and Ilhem Messaoudi",
year = "2013",
month = "1",
day = "29",
doi = "10.1073/pnas.1209591110",
language = "English (US)",
volume = "110",
pages = "1893--1898",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "5",

}

TY - JOUR

T1 - Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates

AU - Marzi, Andrea

AU - Engelmann, Flora

AU - Feldmann, Friederike

AU - Haberthur, Kristen

AU - Shupert, W. Lesley

AU - Brining, Douglas

AU - Scott, Dana P.

AU - Geisbert, Thomas

AU - Kawaoka, Yoshihiro

AU - Katze, Michael G.

AU - Feldmann, Heinz

AU - Messaoudi, Ilhem

PY - 2013/1/29

Y1 - 2013/1/29

N2 - Ebola viruses cause hemorrhagic disease in humans and nonhuman primates with high fatality rates. These viruses pose a significant health concern worldwide due to the lack of approved therapeutics and vaccines as well as their potential misuse as bioterrorism agents. Although not licensed for human use, recombinant vesicular stomatitis virus (rVSV) expressing the filovirus glycoprotein (GP) has been shown to protect macaques from Ebola virus and Marburg virus infections, both prophylactically and postexposure in a homologous challenge setting. However, the immune mechanisms of protection conferred by this vaccine platform remain poorly understood. In this study, we set out to investigate the role of humoral versus cellular immunity in rVSV vaccine-mediated protection against lethal Zaire ebolavirus (ZEBOV) challenge. Groups of cynomolgus macaques weredepleted of CD4+T, CD8+T, or CD20+Bcells beforeand during vaccination with rVSV/ZEBOV-GP. Unfortunately, CD20-depletedanimals generated a robust IgG response. Therefore, an additional group of vaccinated animals were depleted of CD4+ T cells during challenge. All animals were subsequently challenged with a lethal dose of ZEBOV. Animals depleted of CD8+ T cells survived, suggesting a minimal role for CD8+ T cells in vaccine-mediated protection. Depletion of CD4+ T cells during vaccination caused a complete loss of glycoprotein-specific antibodies and abrogated vaccine protection. In contrast, depletion of CD4+ T cells during challenge resulted in survival of the animals, indicating a minimal role for CD4+ T-cell immunityin rVSV-mediated protection. Our results suggest that antibodies playa critical role in rVSV-mediated protection against ZEBOV.

AB - Ebola viruses cause hemorrhagic disease in humans and nonhuman primates with high fatality rates. These viruses pose a significant health concern worldwide due to the lack of approved therapeutics and vaccines as well as their potential misuse as bioterrorism agents. Although not licensed for human use, recombinant vesicular stomatitis virus (rVSV) expressing the filovirus glycoprotein (GP) has been shown to protect macaques from Ebola virus and Marburg virus infections, both prophylactically and postexposure in a homologous challenge setting. However, the immune mechanisms of protection conferred by this vaccine platform remain poorly understood. In this study, we set out to investigate the role of humoral versus cellular immunity in rVSV vaccine-mediated protection against lethal Zaire ebolavirus (ZEBOV) challenge. Groups of cynomolgus macaques weredepleted of CD4+T, CD8+T, or CD20+Bcells beforeand during vaccination with rVSV/ZEBOV-GP. Unfortunately, CD20-depletedanimals generated a robust IgG response. Therefore, an additional group of vaccinated animals were depleted of CD4+ T cells during challenge. All animals were subsequently challenged with a lethal dose of ZEBOV. Animals depleted of CD8+ T cells survived, suggesting a minimal role for CD8+ T cells in vaccine-mediated protection. Depletion of CD4+ T cells during vaccination caused a complete loss of glycoprotein-specific antibodies and abrogated vaccine protection. In contrast, depletion of CD4+ T cells during challenge resulted in survival of the animals, indicating a minimal role for CD4+ T-cell immunityin rVSV-mediated protection. Our results suggest that antibodies playa critical role in rVSV-mediated protection against ZEBOV.

UR - http://www.scopus.com/inward/record.url?scp=84873202509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873202509&partnerID=8YFLogxK

U2 - 10.1073/pnas.1209591110

DO - 10.1073/pnas.1209591110

M3 - Article

VL - 110

SP - 1893

EP - 1898

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 5

ER -